Prostatic artery embolization in the treatment of benign prostatic hyperplasia

short and medium follow-up

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To evaluate the short and mid-term results of prostatic artery embolization in patients with benign prostatic embolization. Retrospective study between March 2009 and June 2011 with 103 patients (mean age 66.8 years, 50-85) that met our inclusion criteria with symptomatic benign prostatic hyperplasia. The clinical outcome was evaluated by the International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of Erectile Function, prostate volume (PV), prostate-specific antigen (PSA), peak urinary flow (Q(max)), and post-void residual volume (PVR) measurements at 3 and 6 months, 1 year, 18 months, and 2 years after PAE and comparison with baseline values was made. Technical and clinical successes, as well as poor clinical outcome definitions, were previously defined. In this review, we evaluate the short and mid-term clinical outcomes and morbidity of patients treated only with non-spherical polyvinyl alcohol. Six months after the procedure, the PV decreased about 23%, IPSS changed to a mean value of 11.95 (almost 50% reduction), the QoL improved slightly more than 2 points, the Q(max) changed to a mean value of 12.63 mL/s, the PVR underwent a change of almost half of the baseline value, and the PSA decreased about 2.3 ng/mL. In the mid-term follow-up and comparing to the baseline values, we still assisted to a reduction in PV, IPSS, QoL, PVR, and PSA, and an increase in Q(max). Prostatic Artery Embolization is a safe procedure with low morbidity that shows good short- and mid-term clinical outcome in our institution.

Original languageEnglish
Pages (from-to)290-3
Number of pages4
JournalTechniques in vascular and interventional radiology
Volume15
Issue number4
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Prostatic Hyperplasia
Prostate
Arteries
Residual Volume
Prostate-Specific Antigen
Quality of Life
Therapeutics
Morbidity
Polyvinyl Alcohol
Retrospective Studies

Keywords

  • Aged
  • Aged, 80 and over
  • Biomarkers
  • Embolization, Therapeutic
  • Humans
  • Kallikreins
  • Male
  • Middle Aged
  • Penile Erection
  • Prostate
  • Prostate-Specific Antigen
  • Prostatic Hyperplasia
  • Quality of Life
  • Retrospective Studies
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome
  • Urodynamics
  • Journal Article

Cite this

@article{d05ba22a9edf4864aa2744699109b6ee,
title = "Prostatic artery embolization in the treatment of benign prostatic hyperplasia: short and medium follow-up",
abstract = "To evaluate the short and mid-term results of prostatic artery embolization in patients with benign prostatic embolization. Retrospective study between March 2009 and June 2011 with 103 patients (mean age 66.8 years, 50-85) that met our inclusion criteria with symptomatic benign prostatic hyperplasia. The clinical outcome was evaluated by the International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of Erectile Function, prostate volume (PV), prostate-specific antigen (PSA), peak urinary flow (Q(max)), and post-void residual volume (PVR) measurements at 3 and 6 months, 1 year, 18 months, and 2 years after PAE and comparison with baseline values was made. Technical and clinical successes, as well as poor clinical outcome definitions, were previously defined. In this review, we evaluate the short and mid-term clinical outcomes and morbidity of patients treated only with non-spherical polyvinyl alcohol. Six months after the procedure, the PV decreased about 23{\%}, IPSS changed to a mean value of 11.95 (almost 50{\%} reduction), the QoL improved slightly more than 2 points, the Q(max) changed to a mean value of 12.63 mL/s, the PVR underwent a change of almost half of the baseline value, and the PSA decreased about 2.3 ng/mL. In the mid-term follow-up and comparing to the baseline values, we still assisted to a reduction in PV, IPSS, QoL, PVR, and PSA, and an increase in Q(max). Prostatic Artery Embolization is a safe procedure with low morbidity that shows good short- and mid-term clinical outcome in our institution.",
keywords = "Aged, Aged, 80 and over, Biomarkers, Embolization, Therapeutic, Humans, Kallikreins, Male, Middle Aged, Penile Erection, Prostate, Prostate-Specific Antigen, Prostatic Hyperplasia, Quality of Life, Retrospective Studies, Surveys and Questionnaires, Time Factors, Treatment Outcome, Urodynamics, Journal Article",
author = "{Rio Tinto}, Hugo and Jo{\~a}o Pisco and Tiago Bilhim and Marisa Duarte and L{\'u}cia Fernandes and Jos{\'e} Pereira and Pinheiro, {Luis Campos}",
note = "Copyright {\circledC} 2012 Elsevier Inc. All rights reserved.",
year = "2012",
month = "12",
doi = "10.1053/j.tvir.2012.09.005",
language = "English",
volume = "15",
pages = "290--3",
journal = "Techniques in vascular and interventional radiology",
issn = "1557-9808",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Prostatic artery embolization in the treatment of benign prostatic hyperplasia

T2 - short and medium follow-up

AU - Rio Tinto, Hugo

AU - Pisco, João

AU - Bilhim, Tiago

AU - Duarte, Marisa

AU - Fernandes, Lúcia

AU - Pereira, José

AU - Pinheiro, Luis Campos

N1 - Copyright © 2012 Elsevier Inc. All rights reserved.

PY - 2012/12

Y1 - 2012/12

N2 - To evaluate the short and mid-term results of prostatic artery embolization in patients with benign prostatic embolization. Retrospective study between March 2009 and June 2011 with 103 patients (mean age 66.8 years, 50-85) that met our inclusion criteria with symptomatic benign prostatic hyperplasia. The clinical outcome was evaluated by the International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of Erectile Function, prostate volume (PV), prostate-specific antigen (PSA), peak urinary flow (Q(max)), and post-void residual volume (PVR) measurements at 3 and 6 months, 1 year, 18 months, and 2 years after PAE and comparison with baseline values was made. Technical and clinical successes, as well as poor clinical outcome definitions, were previously defined. In this review, we evaluate the short and mid-term clinical outcomes and morbidity of patients treated only with non-spherical polyvinyl alcohol. Six months after the procedure, the PV decreased about 23%, IPSS changed to a mean value of 11.95 (almost 50% reduction), the QoL improved slightly more than 2 points, the Q(max) changed to a mean value of 12.63 mL/s, the PVR underwent a change of almost half of the baseline value, and the PSA decreased about 2.3 ng/mL. In the mid-term follow-up and comparing to the baseline values, we still assisted to a reduction in PV, IPSS, QoL, PVR, and PSA, and an increase in Q(max). Prostatic Artery Embolization is a safe procedure with low morbidity that shows good short- and mid-term clinical outcome in our institution.

AB - To evaluate the short and mid-term results of prostatic artery embolization in patients with benign prostatic embolization. Retrospective study between March 2009 and June 2011 with 103 patients (mean age 66.8 years, 50-85) that met our inclusion criteria with symptomatic benign prostatic hyperplasia. The clinical outcome was evaluated by the International Prostate Symptom Score (IPSS), quality of life (QoL), International Index of Erectile Function, prostate volume (PV), prostate-specific antigen (PSA), peak urinary flow (Q(max)), and post-void residual volume (PVR) measurements at 3 and 6 months, 1 year, 18 months, and 2 years after PAE and comparison with baseline values was made. Technical and clinical successes, as well as poor clinical outcome definitions, were previously defined. In this review, we evaluate the short and mid-term clinical outcomes and morbidity of patients treated only with non-spherical polyvinyl alcohol. Six months after the procedure, the PV decreased about 23%, IPSS changed to a mean value of 11.95 (almost 50% reduction), the QoL improved slightly more than 2 points, the Q(max) changed to a mean value of 12.63 mL/s, the PVR underwent a change of almost half of the baseline value, and the PSA decreased about 2.3 ng/mL. In the mid-term follow-up and comparing to the baseline values, we still assisted to a reduction in PV, IPSS, QoL, PVR, and PSA, and an increase in Q(max). Prostatic Artery Embolization is a safe procedure with low morbidity that shows good short- and mid-term clinical outcome in our institution.

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers

KW - Embolization, Therapeutic

KW - Humans

KW - Kallikreins

KW - Male

KW - Middle Aged

KW - Penile Erection

KW - Prostate

KW - Prostate-Specific Antigen

KW - Prostatic Hyperplasia

KW - Quality of Life

KW - Retrospective Studies

KW - Surveys and Questionnaires

KW - Time Factors

KW - Treatment Outcome

KW - Urodynamics

KW - Journal Article

U2 - 10.1053/j.tvir.2012.09.005

DO - 10.1053/j.tvir.2012.09.005

M3 - Article

VL - 15

SP - 290

EP - 293

JO - Techniques in vascular and interventional radiology

JF - Techniques in vascular and interventional radiology

SN - 1557-9808

IS - 4

ER -